Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21.

MLA

Masago, Katsuhiro, et al. “Good Clinical Response to Erlotinib in a Patient with Anaplastic Thyroid Carcinoma Harboring an Epidermal Growth Factor Somatic Mutation, L858R, in Exon 21.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 29, no. 16, June 2011, pp. e465–67. EBSCOhost, https://doi.org/10.1200/JCO.2010.34.0216.

APA

Masago, K., Miura, M., Toyama, Y., Togashi, Y., & Mishima, M. (2011). Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 29(16), e465–e467. https://doi.org/10.1200/JCO.2010.34.0216

Chicago

Masago, Katsuhiro, Masako Miura, Yoshiro Toyama, Yosuke Togashi, and Michiaki Mishima. 2011. “Good Clinical Response to Erlotinib in a Patient with Anaplastic Thyroid Carcinoma Harboring an Epidermal Growth Factor Somatic Mutation, L858R, in Exon 21.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29 (16): e465–67. doi:10.1200/JCO.2010.34.0216.